Actively Recruiting
A Study of Olomorasib (LY3537982) in Healthy Participants
Led by Eli Lilly and Company · Updated on 2026-03-23
15
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study in healthy participants is to determine the effect of fluconazole on the amount of study drug that gets into the bloodstream and how long it takes the body to get rid of it. For each participant, the study will last up to approximately 7 weeks and will require 12 overnight stays in the research center.
CONDITIONS
Official Title
A Study of Olomorasib (LY3537982) in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Must have a Body Mass Index (BMI) within the range of 18.0 to 30.0 kilograms per square meter (kg/m2)
- Participants assigned male at birth (AMAB) or participants assigned female at birth (AFAB) who are individuals not of childbearing potential (INOCBP).
You will not qualify if you...
- History or presence of metabolic disease
- History or presence of biliary disease
- History or presence of gastrointestinal disease
- History or presence of hematological disease
- History or presence of neurological disease
- Significant history of hepatic disease
- Clinically significant, active cardiovascular disease or history of myocardial infarction within 6 months prior to Day 1
- Abnormal blood pressure or pulse rate
- 12-lead electrocardiogram (ECG) abnormality that increases risks or may confound analysis
- History of malignancy within 5 years prior to screening, except certain skin or cervical cancers resected with no metastatic disease for 3 years
- Evidence of Human Immunodeficiency Virus (HIV) infection or positive HIV antibodies
- Positive hepatitis C antibody test
- Evidence of hepatitis B at screening (positive surface antigen, HBV DNA, or both)
- Alcohol intake exceeding recommended weekly limits per local regulation
- Use of tobacco, smoking-cessation products, electronic (e)-cigarettes, or nicotine products within 90 days prior to first olomorasib administration and through the end of trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, United States, 32117-5116
Actively Recruiting
Research Team
T
There may be multiple sites in this clinical trial. (Add "This 1-877-CTLILLY (1-877-285-4559) or
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here